Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HOPE 1
- Development stage
- Phase 3
- Lead developer
- Zelira Therapeutics
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
HOPE 1 is a proprietary cannabinoid-based medicinal product developed by Zelira Therapeutics for the treatment of autism spectrum disorder (ASD) and Phelan-McDermid Syndrome. It is a 1:1 formulation of tetrahydrocannabinol (THC) and cannabidiol (CBD) at a concentration of 5 mg/mL each, delivered in a pharmaceutical-grade olive oil tincture for sublingual administration. The drug aims to manage symptoms associated with ASD and is currently undergoing FDA-regulated clinical trials. HOPE 1 was launched in Australia in October 2020 and has been distributed in several U.S. states under medicinal cannabis programs while advancing through the formal FDA approval pathway.
- Brand names
- HOPE
- Other names
- HOPE 1HOPE1HOPE-1
02
Targets
CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV (TRPV channel family)
Beyond the preview
Go deeper on HOPE 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HOPE 1.